---
title: "Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284804718.md"
description: "Stifel Nicolaus analyst Thomas Stephan has maintained a Hold rating on Bausch + Lomb Corporation (BLCO) with a price target of $16.00. He has an average return of 2.1% and a 40% success rate on his stock recommendations. Additionally, Barclays also issued a Hold rating, while Citi maintained a Buy rating on the company."
datetime: "2026-04-30T15:26:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284804718.md)
  - [en](https://longbridge.com/en/news/284804718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284804718.md)
---

# Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation today and set a price target of $16.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Stephan covers the Healthcare sector, focusing on stocks such as TransMedics Group, Glaukos, and Alphatec Holdings. According to TipRanks, Stephan has an average return of 2.1% and a 40.00% success rate on recommended stocks.

In addition to Stifel Nicolaus, Bausch + Lomb Corporation also received a Hold from Barclays’s Matt Miksic in a report issued today. However, on the same day, Citi maintained a Buy rating on Bausch + Lomb Corporation (NYSE: BLCO).

### Related Stocks

- [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [TMDX.US](https://longbridge.com/en/quote/TMDX.US.md)
- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)
- [ATEC.US](https://longbridge.com/en/quote/ATEC.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Short Interest in Bausch + Lomb Corporation (NYSE:BLCO) Increases By 50.7%](https://longbridge.com/en/news/280886928.md)
- [Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday](https://longbridge.com/en/news/283635818.md)
- [Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)](https://longbridge.com/en/news/286568281.md)
- [Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)](https://longbridge.com/en/news/286587770.md)
- [Stifel Nicolaus Keeps Their Buy Rating on CAVA Group, Inc. (CAVA)](https://longbridge.com/en/news/286598475.md)